dsip

This study developed a DSIP fusion peptide with cell-penetrating Tat sequence (DSIP-CBBBP) to enhance blood-brain barrier penetration, addressing DSIP's delivery limitations. Using PCPA-induced insomnia mice, researchers evaluated sleep-promoting effects and neurotransmitter modulation. The fusion peptide successfully expressed in Pichia pastoris showed superior BBB crossing ability. Treatment influenced serotonin, glutamate, dopamine, and melatonin levels, demonstrating neurotransmitter balance restoration. Results support DSIP-CBBBP's potential as an improved therapeutic approach for sleep disorders, combining DSIP's sleep-regulating properties with enhanced CNS delivery through the cell-penetrating peptide technology.

In this double-blind crossover study with six healthy volunteers, intravenous DSIP administration (25 nmol/kg) produced immediate sleep pressure with total sleep time increasing by 59% within 130 minutes compared to placebo. Delayed effects on subsequent night sleep included shorter sleep onset, reduced stage 1 sleep percentage, and improved sleep efficiency. Sophisticated EEG and behavioral analyses revealed no classic sedative effects, suggesting DSIP sustains natural sleep functions rather than inducing pharmacological sedation. The compound was well-tolerated with no psychological, physiologic, or biochemical side effects observed during the study period.

This double-blind matched-pairs study investigated DSIP's effects in 16 chronic insomnia patients over five consecutive laboratory nights. Patients received 25 nmol/kg intravenous DSIP or placebo before nights 3-5. Polysomnography revealed higher sleep efficiency and shorter sleep latency with DSIP compared to placebo, along with decreased subjective tiredness measures. However, data analysis suggested effects were statistically weak and partially attributable to placebo group variations. Researchers concluded short-term DSIP treatment showed limited major therapeutic benefit for chronic insomnia despite objective improvements in some sleep parameters.

This preclinical study investigated intranasal DSIP treatment (120 µg/kg for 8 days) in rats subjected to middle cerebral artery occlusion-induced stroke. While brain infarction volume showed no significant difference between DSIP-treated and vehicle groups, motor performance in the rotarod test significantly recovered in DSIP-treated animals. Testing on days 1, 3, 7, 14, and 21 post-stroke revealed progressive motor coordination improvements only in the DSIP group, confirmed by linear regression analysis showing positive dynamics. Results suggest DSIP accelerates motor function recovery after stroke through mechanisms potentially independent of infarct size reduction, warranting future studies on optimal dosing regimens.

Based on evidence that DSIP possesses agonistic activity on opiate receptors (effects reversed by Naloxone in animal models), this study administered intravenous DSIP (25 nmol/kg) as sole treatment to 67 patients presenting withdrawal symptoms (28 from alcohol, 39 from opiates). Of 49 evaluable patients, DSIP produced beneficial effects in 48 cases (22 alcoholics, 26 of 27 opiate addicts), with immediate onset of action and sustained suspension of somatic symptoms. Anxiety resolved within hours. No major side effects occurred, suggesting DSIP offers a physiologically-based approach for treating established withdrawal syndrome.

This larger study administered DSIP intravenously to 107 inpatients presenting with alcohol (n=47) or opiate (n=60) withdrawal symptoms. Assessment by physicians and nursing staff showed approximately 87% of evaluable patients in both groups responded favorably. The therapeutic hypothesis was based on Tissot's animal studies showing morphine, alcohol, pentobarbital, and DSIP all induced slow-wave sleep with spindles when injected into the bulbo-mesencephalo-thalamic recruiting system—effects reversed by Naloxone—suggesting DSIP's agonistic activity on opiate receptors might benefit withdrawal treatment. Results supported clinical utility in managing both alcohol and opiate withdrawal syndromes.